Open AccessImage-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake
Author(s) -
Andrew Samoyedny,
Abhay Srinivasan,
Lisa J. States,
Yaël P. Mossé,
Emma Alai,
Bruce Pawel,
Jennifer Pogoriler,
Sphoorti Shellikeri,
Seth Vatsky,
Michael Acord,
Fernando Escobar,
J. Christopher Edgar,
John M. Maris,
Anne Marie Cahill
Publication year - 2021
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.20.00171
Subject(s) - biopsy , medicine , soft tissue , neuroblastoma , lesion , radiology , nuclear medicine , pathology , biology , genetics , cell culture
Many novel therapies for relapsed and refractory neuroblastoma require tumor tissue for genomic sequencing. We analyze our experience with image-guided biopsy in these patients, focusing on safety, yield, adequacy for next-generation sequencing (NGS), and correlation of tumor cell percent (TC%) with quantitative uptake on 123 I-meta-iodobenzylguanidine (MIBG) single-photon emission computed tomography with computed tomography (SPECT/CT).